# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 pric...
Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fr...
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $222 price target.
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $2.68 per share which missed the analyst consensus estimate o...
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $180 ...